Organon pays up to $1.2B to acquire Dermavant and its steroid …
WEBSep 18, 2024 · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in ...
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
WEBSep 18, 2024 · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...
Organon to Acquire Dermavant including its Innovative …
WEB6 days ago · JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
News & Media - Dermavant
WEBJun 25, 2024 · Find the latest news and public announcements from Dermavant Sciences including investor information, pipeline updates and more.
Roivant's Sale Of Dermavant To Organon: Win-Win In Atopic …
WEB5 days ago · From a valuation perspective, ROIV will receive up to $1.2 billion from its Dermavant sale to OGN. However, only $175.0 million is an upfront cash payment, and the rest is contingent on milestones ...
Organon to acquire Dermavant, Vtama cream in definitive …
WEB5 days ago · Organon and Dermavant have entered a definitive agreement in which Organon will acquire Dermavant, according to a press release. Organon is an independent global health care company dedicated to ...
New Data from Phase 4 Trial of VTAMA® (tapinarof) Cream, 1 ... - Dermavant
WEBOct 16, 2023 · On May 24, 2022, Dermavant announced the FDA approved VTAMA ® (tapinarof) cream, 1% for the treatment of adult plaque psoriasis. The approval made VTAMA cream the first non-steroidal topical novel chemical entity launched for psoriasis in the U.S. in more than 25 years.
Dermavant Announces Positive Results from Phase 4 Open-Label …
WEBDec 6, 2023 · LONG BEACH, Calif. & BASEL, Switzerland-- ( BUSINESS WIRE )--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in...
Dermavant Announces Positive Data from the ADORING Phase 3 …
WEBJan 11, 2024 · Dermavant completed an interim analysis of data from ADORING 3. The company also completed a planned integrated analysis of data including 711 patients from ADORING 1, ADORING 2, ADORING 3 and...
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for
WEBMay 24, 2022 · As the first and only approved drug in its class in the U.S., the FDA’s approval of VTAMA cream provides an effective new non-steroidal treatment option for millions of adults living with plaque ...